

## ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018


Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE, 2020

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 30/06/2020	3 months ended 31/03/2020	3 months ended 30/06/2019	12 months ended 31/03/2020
		Unaudited	Audited	Unaudited	Audited
(1)	(2)	(3)	(4)	(5)	(6)
I.	Revenue from operations	12,424.77	7,205.25	8,489.43	30,695.96
II.	Other income	309.64	110.63	125.64	421.23
III.	<b>Total Revenue (I + II)</b>	<b>12,734.41</b>	<b>7,315.88</b>	<b>8,615.07</b>	<b>31,117.19</b>
IV.	Expenses:				
	Cost of materials consumed	6,676.20	6,600.16	5,889.60	23,965.58
	Purchases of Stock-in-Trade	173.75	34.06	89.84	401.45
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	1,753.09	(1,539.07)	664.08	(1,350.76)
	Employee benefits expense	344.29	370.52	312.38	1,336.23
	Finance costs	44.80	54.54	7.93	79.22
	Depreciation and amortization expense	373.04	406.64	91.98	703.26
	Other expenses	1,139.08	1,550.68	761.68	4,066.65
	<b>Total expenses (IV)</b>	<b>10,504.25</b>	<b>7,477.53</b>	<b>7,817.49</b>	<b>29,201.63</b>
V.	<b>Profit / (Loss) before exceptional and items and tax (III - IV)</b>	<b>2,230.16</b>	<b>(161.65)</b>	<b>797.58</b>	<b>1,915.56</b>
VI.	Exceptional items	-	-	-	-
VII.	<b>Profit / (Loss) before tax (V - VI)</b>	<b>2,230.16</b>	<b>(161.65)</b>	<b>797.58</b>	<b>1,915.56</b>
VIII	Tax expense:				
	(1) Current tax	549.00	(196.00)	214.00	370.00
	(2) Deferred tax	9.06	142.02	(3.79)	130.70
	(3) MAT Credit Entitlement	-	(15.67)	-	(15.67)
		<b>558.06</b>	<b>(69.65)</b>	<b>210.21</b>	<b>485.03</b>
IX	<b>Profit/(Loss) after Tax (VII-VIII)</b>	<b>1,672.10</b>	<b>(92.00)</b>	<b>587.37</b>	<b>1,430.53</b>
X	Other Comprehensive Income (net of Tax)				
	(i) Items that will not be reclassified to profit or loss	10.59	3.15	(7.61)	(9.22)
	(ii) Items that will be reclassified to profit or loss	-	-	-	-
	<b>Total Other Comprehensive Income (net of Tax)</b>	<b>10.59</b>	<b>3.15</b>	<b>(7.61)</b>	<b>(9.22)</b>
XI	<b>Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)</b>	<b>1,682.69</b>	<b>(88.85)</b>	<b>579.76</b>	<b>1,421.31</b>
	Paid up Equity Share Capital (Face value Rs. 5/- each)	1,252.80	1,252.80	1,252.80	1,252.80
	Other Equity (excluding revaluation reserves)				14,967.94
XII	Earnings per equity share (Non annualised) (In Rs.)				
	(1) Basic	6.67	(0.37)	2.34	5.71
	(2) Diluted	6.67	(0.37)	2.34	5.71

See accompanying notes to the financial results



Notes:-

1. The results of the quarter ended 30th June,2020 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 07th August, 2020. The statutory auditors of the company carried out a "Limited Review" of the financial results for quarter ended 30th June ,2020.

2. Other Financial indicators

(Rs. in Lakhs)

Particulars	3 months ended 30/06/2020	3 months ended 31/03/2020	3 months ended 30/06/2019	12 months ended 31/03/2020
EBITDA	2,648.00	299.53	897.49	2,698.04
% of EBITDA Margin	21.31	4.16	10.57	8.79
EBITDA (Adjusted to Forex (gain) / loss and Mark to Market (gain) / loss on Investment in Mutual funds)	2,736.53	840.32	840.07	3,433.09
% of Adjusted EBITDA Margin	22.02	11.66	9.90	11.18

3. The figures for the quarter ended 31st March, 2020 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.

4. The Board of Directors has recommended issue of bonus shares in the ratio of 1 equity share of Rs.5/- each for every 1 equity share of Rs.5/- each ( 1:1 ),which is subject to the approval of members of the Company by way of ordinary resolution through upcoming AGM and e-voting.

5. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

6. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Limited

*Bipin N. Shah*

Bipin N. Shah  
Managing Director

(DIN: 00083244)




Place : Mumbai

Dated : 07<sup>th</sup> August, 2020

**Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to The Board of Directors  
Anuh Pharma Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Anuh Pharma Limited (the "Company") for the quarter ended June 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **JAYANTILAL THAKKAR & CO.**  
**CHARTERED ACCOUNTANTS**  
**(FIRM REG. NO. 104133W)**



**PLACE: Mumbai**  
**DATE: 7<sup>th</sup> August, 2020**

*V. A. Merchant*

**VIRAL A. MERCHANT**  
**PARTNER**

**MEMBERSHIP NO. 116279**

**UDIN: 20116279AAAAAY7205**